Germline Determinants of Toxicity and Efficacy in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 Autologous CAR T-Cell Therapy

被引：0

作者：

Strati, Paolo ^{[1
]}

Brandt, Amanda ^{[2
]}

Henderson, Jared ^{[3
]}

Westin, Jason ^{[1
]}

Nastoupil, Loretta J. ^{[2
]}

Al Zaki, Ajlan ^{[4
]}

Jallouk, Andrew P. ^{[5
]}

Adkins, Sherry

Shpall, Elizabeth J. ^{[6
]}

Kebriaei, Partow ^{[6
]}

Ramdial, Jeremy ^{[6
]}

Saini, Neeraj Y. ^{[6
]}

Ahmed, Sairah ^{[7
]}

Flowers, Christopher R. ^{[1
]}

Neelapu, Sattva S. ^{[1
]}

Hildebrandt, Michelle ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Lymphoma Myeloma, Houston, TX 77030 USA

[5] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA

[7] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma & Stem Cell Transplantat, Houston, TX 77030 USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180744

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
Hirayama, Alexandre V.
Kimble, Erik L.
Wright, Jocelyn H.
Fiorenza, Salvatore
Gauthier, Jordan
Voutsinas, Jenna M.
Wu, Qian
Yeung, Cecilia C. S.
Gazeau, Nicolas
Pender, Barbara S.
Kirchmeier, Delaney R.
Torkelson, Aiko
Chutnik, Abigail N.
Cassaday, Ryan D.
Chapuis, Aude G.
Green, Damian J.
Kiem, Hans -Peter
Milano, Filippo
Shadman, Mazyar
Till, Brian G.
Riddell, Stanley R.
Maloney, David G.
Turtle, Cameron J.
BLOOD ADVANCES, 2024, 8 (02) : 453 - 467
[32] Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma
Newsam, Austin D.
Coughlin, Caroline A.
Trabolsi, Asaad
Schatz, Jonathan H.
LEUKEMIA & LYMPHOMA, 2023, 64 (14) : 2217 - 2224
[33] Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study
Tun, Aung M.
Patel, Romil D.
St-Pierre, Frederique
Ouchveridze, Evguenia
Niu, Alex
Thordardottir, Thorunn
Obasi, Jennifer
Rosenthal, Allison
Pophali, Priyanka A.
Fenske, Timothy S.
Karmali, Reem
Ahmed, Sairah
Johnston, Patrick B.
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1712 - 1720
[34] Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma
Hashmi, Hamza
Darwin, Alicia
Bachmeier, Christina A.
Chavez, Julio
Shah, Bijal
Ibarz, Javier Pinilla
Nishihori, Taiga
Khimani, Farhad
Lazaryan, Aleksandr
Liu, Hien D.
Davila, Marco L.
Locke, Frederick L.
Jain, Michael D.
BLOOD, 2019, 134
[35] Anti-CD19 CAR T cell therapy for lymphoma - off to the races!
Maloney, David G.
NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (05) : 279 - 280
[36] Anti-CD19 CAR T cell therapy for lymphoma — off to the races!
David G. Maloney
Nature Reviews Clinical Oncology, 2019, 16 : 279 - 280
[37] CAR T-cell therapy in diffuse large B-cell lymphoma
Hopfinger, Georg
Worel, Nina
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (01) : 32 - 35
[38] CAR T-cell therapy in refractory large B-cell lymphoma
Stirrups, Robert
LANCET ONCOLOGY, 2018, 19 (01): : E19 - E19
[39] CAR T-cell therapy in diffuse large B-cell lymphoma
Georg Hopfinger
Nina Worel
memo - Magazine of European Medical Oncology, 2020, 13 : 32 - 35
[40] Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
Zhang, Xian
Lu, Xin-an
Yang, Junfang
Zhang, Gailing
Li, Jingjing
Song, Lisong
Su, Yunchao
Shi, Yanze
Zhang, Min
He, Jiujiang
Song, Dan
Lv, Fanyong
Li, Wenqian
Wu, Yan
Wang, Hui
Liu, Hongxing
Zhou, Xiaosu
He, Ting
Lu, Peihua
BLOOD ADVANCES, 2020, 4 (10) : 2325 - 2338

← 1 2 3 4 5 →